Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome

NCT03697161 is registered in ClinicalTrials.gov with Healx AI as lead sponsor.

NCT NCT03697161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03697161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome
Lead sponsor
Healx AI
Phase
Phase 2
Overall status
Completed
Start date
September 17, 2018
Completion date
February 26, 2020
Enrollment
36 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome (fxs)